CM
ACAD icon

Capula Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Capula Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,670
Closed -$293K – 633
2025
Q1 		$293K Buy
+17,670
New +$321K ﹤0.01% 402
2021
Q3 		– Sell
-15,012
Closed -$366K – 830
2021
Q2 		$366K Buy
+15,012
New +$339K 0.01% 525

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Capula Management's ACAD Position: Q2 2025 in Review

Capula Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 17,670 shares — an estimated $293K sold.

Capula Management first reported a position in ACAD in Q2 2021 and held it in 2 quarters. The position peaked at $366K in Q2 2021. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Capula Management reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capula Management sold 17,670 Acadia Pharmaceuticals shares in Q2 2025, an estimated $293K.
  • Capula Management first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Capula Management's Acadia Pharmaceuticals position peaked at $366K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.